NCT05028777 Cohort of Patients With Left Ventricular Thrombus: Management and Outcomes in the Direct Oral Anticoagulants Era
| NCT ID | NCT05028777 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Insel Gruppe AG, University Hospital Bern |
| Condition | Thrombus of Left Ventricle |
| Study Type | OBSERVATIONAL |
| Enrollment | 550 participants |
| Start Date | 2021-01-01 |
| Primary Completion | 2026-02-28 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 550 participants in total. It began in 2021-01-01 with a primary completion date of 2026-02-28.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The investigators' primary objective is to assess whether a difference in the occurrence of bleeding events exist between patients with LVT treated with DOACs as compared to those treated with VKAs.
Eligibility Criteria
Inclusion Criteria: * Patients at least 18 years old at enrolment * With a LVT identified at echocardiography, MRI or CT between January 1st, 2013 and July 31st, 2020 * Treated at least once at the Inselspital or in another site of the Insel Gruppe * Able to provide a written informed consent Exclusion Criteria: * Documented refusal
Contact & Investigator
Christoph Gräni, Prof. PHD
PRINCIPAL INVESTIGATOR
Department of Cardiology, University Hospital Bern
Frequently Asked Questions
Who can join the NCT05028777 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Thrombus of Left Ventricle. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05028777 currently recruiting?
Yes, NCT05028777 is actively recruiting participants. Contact the research team at christoph.graeni@insel.ch for enrollment information.
Where is the NCT05028777 trial being conducted?
This trial is being conducted at Bern, Switzerland.
Who is sponsoring the NCT05028777 clinical trial?
NCT05028777 is sponsored by Insel Gruppe AG, University Hospital Bern. The principal investigator is Christoph Gräni, Prof. PHD at Department of Cardiology, University Hospital Bern. The trial plans to enroll 550 participants.